Dr. Dan Barouch

Person

Mentions

Episodes

Claims

Dr. Dan Barouch, mentioned 10 times across podcast episodes and expert conversations analyzed by Sonic.

What Dr. Dan Barouch has said

Dr. Dan Barouch's research work includes HIV, adenoviral vector platforms, and the science underlying the single-dose Ad26 COVID-19 vaccine approach.

neutral·David Williams

According to the CDC, the influenza vaccine has demonstrated an effectiveness of 19% to 60% over the last 20 years.

neutral·Dr. Dan Barouch

Existing vaccines for the Ebola Zaire strain are believed to be ineffective or less effective against the Bundibugyo strain due to genetic differences.

bearish·Dr. Dan Barouch

Dr. Dan Barouch's research work includes HIV, adenoviral vector platforms, and the science underlying the single-dose Ad26 COVID-19 vaccine approach.

Expert perspectiveDavid WilliamsJul 1

According to the CDC, the influenza vaccine has demonstrated an effectiveness of 19% to 60% over the last 20 years.

Expert perspectiveDr. Dan BarouchJul 1

Existing vaccines for the Ebola Zaire strain are believed to be ineffective or less effective against the Bundibugyo strain due to genetic differences.

Expert perspectiveDr. Dan BarouchJul 1

In experimental models, mucosal delivery of the Rhesus Ad Platform has led to substantially improved protection against pathogens such as COVID-19 and influenza.

Expert perspectiveDr. Dan BarouchJul 1

The rare thrombosis side effect associated with some adenoviral vaccines is believed to be caused by cross-reactivity of the adenovirus p7 protein, which leads to antibodies that bind to the human coa...

Expert perspectiveDr. Dan BarouchJul 1

The Riovax rhesus adenoviral vector platform is expected to have an efficacy advantage over human adenoviral platforms because there is no pre-existing baseline immunity to the rhesus vectors in the h...

Expert perspectiveDr. Dan BarouchJul 1

The rhesus adenovirus platform developed by Vector Sciences is intended to improve upon prior adenovirus platforms by providing enhanced efficacy and safety features.

Expert perspectiveDr. Dan BarouchJul 1

The Riovax platform's p7 protein lacks the key epitopes linked to the thrombosis side effect seen in other adenoviral vaccines, which is expected to provide a safety advantage.

Expert perspectiveDr. Dan BarouchJul 1

The AstraZeneca and Johnson & Johnson COVID-19 vaccines caused a thrombosis side effect in approximately 3 out of one million cases.

Expert perspectiveDr. Dan BarouchJul 1

There are currently licensed vaccines for the Ebola virus, one based on a vesicular stomatitis virus (VSV) vector and another based on the Ad26 adenovirus vector.

Expert perspectiveDr. Dan BarouchJul 1

Create a free account to see Dr. Dan Barouch's full intelligence report — every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail